Inactivated vaccine

$82 Billion Global Vaccines Market 2023 to 2029: Growth Trends, and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, SEARO, Influenza, Vaccine, WPRO, AMRO, Sanofi, Inactivated vaccine, Merck, Projection, COVID-19, Human papillomavirus infection, Pneumococcal conjugate vaccine, Anthrax Vaccine Immunization Program, GSK, Overalls, Mortality, PCV, Streptococcus pneumoniae, HPV, WHO, Chickenpox, Conjugate vaccine, Pharmaceutical industry

This is likely to be a continuous booster to the PCV segment in vaccines market.

Key Points: 
  • This is likely to be a continuous booster to the PCV segment in vaccines market.
  • This according to the report will act as a significant driving force for spike in demand for PCV in global vaccines market.
  • These markets are expected to capture around 50% of the overall vaccines market valuation over the next few years.
  • The report marks AMRO as the most prominent vaccines market as the region is characterized by the relatively high value for Influenza (adult), Varicella, meningococcal vaccines, and HPV.

U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

Retrieved on: 
Wednesday, December 28, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Meningococcal disease, PDUFA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prescription Drug User Fee Act, Vaccination, BLA, Death, Naphthoate synthase, Inc., Disease, Patient, Mortality, NYSE, Serotype, Development, IMD, PFE, ACIP, Survivor, Safety, FDA, Vaccine, Senior, Biologics license application, Inactivated vaccine, Pharmaceutical industry, Pfizer

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY).
  • Pfizer submitted MenABCWY for the prevention of meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age.
  • The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA on the pentavalent meningococcal vaccine application is in October 2023.
  • “We believe our investigational MenABCWY vaccine, if approved and recommended, could help simplify the meningococcal vaccination schedule for adolescents and young adults, and in turn improve vaccination rates, and provide the broadest serogroup coverage of any meningococcal vaccine.

Worldwide Vaccines Industry to 2029 - Combination Vaccines Remain a Significant Growth Contributor to Vaccine Spaces

Retrieved on: 
Friday, January 6, 2023
SEARO, Influenza, CSL Limited, Vaccine, WPRO, AMRO, Merck, Inactivated vaccine, Projection, COVID-19, Human papillomavirus infection, Pneumococcal conjugate vaccine, Anthrax Vaccine Immunization Program, GSK, Growth, Overalls, Mortality, PCV, Streptococcus pneumoniae, Mitsubishi Tanabe Pharma, Serum Institute of India, HPV, China National Pharmaceutical Group, Emergent BioSolutions, WHO, Chickenpox, Emergent, Conjugate vaccine, Pharmaceutical industry, Sanofi, Pfizer, Waldemar Haffkine

Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.

Key Points: 
  • Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.
  • While vaccines market (excluding COVID-19 vaccine) is expected to demonstrate nearly 11.2% growth, the market (including COVID-19 vaccine) is likely to experience 3.9% growth through the end of forecast period.
  • Epidemic, and pandemic situations like COVID-19 outbreak act as the key growth influencers for vaccines market, says a newly released market intelligence report of The publisher.
  • On the other hand, demand for seasonal influenza vaccines is projected to remain buoyant and will see the fastest growth through 2029.

Microbial Fermentation Technology Market Trends/Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Biotechnology, Pharmaceutical, Health, Genomatica, Metabolic engineering, SUB, National Biotechnology Research Park, Cargill, CSR, ABEC, CMOS, Cyclone, Agitation, Inactivated vaccine, Tropical cyclone engineering, SWOT, Fermentation, USD, Growth, Biopharmaceutical, Hormone, Fine chemical, Vaccine

The "Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Application (Antibiotics, Vaccines), by End-use (Biopharmaceutical Companies), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Application (Antibiotics, Vaccines), by End-use (Biopharmaceutical Companies), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Since fermentation is observed to be of utmost importance in the manufacturing of biopharmaceuticals, there is also a growing demand for microbial fermentation technology in biopharmaceutical manufacturing.
  • The newly installed solutions are expected to provide a faster turnaround time with high-growth microbial fermentation on large scale.
  • Furthermore, technological advances in microbial fermentation platforms are also expected to supplement the market growth.

EQS-News: LINDIS Biotech Presented Encouraging Data from Non-Muscle-Invasive Bladder Cancer Patients Treated with Trifunctional Antibody CATUMAXOMAB at EMUC22

Retrieved on: 
Sunday, November 27, 2022
CR, Recurrence, Cancer, Immune system, Congress, Macrophage, Șaeș, CRS, Risk, NMIBC, Inactivated vaccine, Urine, CIS, Carcinoma, Health, Patient, Urinary bladder, Toxicity, Cystectomy, Neoplasm, Ascites, European, Monoclonal antibody, BCG, AES, Quality of life, Bladder cancer, Data monitoring committee, Hope, B cell, Abdomen, Epithelial cell adhesion molecule, Safety, Pharmaceutical industry, Vaccine, Catumaxomab

Consistent with previous findings, CATUMAXOMAB was well tolerated, and there was no dose limiting toxicity.

Key Points: 
  • Consistent with previous findings, CATUMAXOMAB was well tolerated, and there was no dose limiting toxicity.
  • Treatment emergent adverse events (AEs) were only of grade 1-2, no serious adverse events (SAEs) were observed.
  • Our previously released compassionate use data, as well as the positive results and follow-up data from the dose escalation are strongly encouraging.
  • The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells.

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

Retrieved on: 
Thursday, November 10, 2022
GLOBE, AOM, S&P, Moraxella catarrhalis, Income, Vaccine, Accounting, Research, Pneumonia, Inactivated vaccine, Travel, Mouse, PCV13, Board, Streptococcus pneumoniae, G&A, Monkeypox, Share repurchase, Haemophilus influenzae, Antibody, CA, Development, Infection, Gastroenteritis, Time, Company, BWV, Disease, Water, Conference, Norovirus, VUK, Private law, Administration, Rotavirus, Cincinnati Children's Hospital Medical Center, Antigen, Congress, Pharmaceutical industry, Insurance, Haemophilus, Jude the Apostle, Streptococcus

On August 11, 2022, BWV closed a private placement with aggregate net cash proceeds of approximately $8.7 million.

Key Points: 
  • On August 11, 2022, BWV closed a private placement with aggregate net cash proceeds of approximately $8.7 million.
  • On November 8, 2022, the Company announced the appointment of Vuk Jeremi to its Board on November 4, 2022.
  • On November 9, 2022, the Board approved a share repurchase program to allow for the Company to repurchase up to 5 million shares, with discretion to management to make purchases subject to market conditions.
  • Cash Position: Cash was $29.1 million as of September 30, 2022, as compared to $1.9 million as of December 31, 2021.

Global Respiratory Disease Vaccine Market Report 2022: Increasing R&D Expenditure by Leading Companies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Health, Infectious Diseases, Other Health, COVID-19, Pharmaceutical, Biotechnology, Adolescence, Geography, Profile, Inactivated vaccine, Whooping cough, Porter W Anderson Jr., Vaccination, CAGR, Industry, Adult, Streptococcus pneumoniae, Global, COVID-19, USD, Infection, Infant, Observation, Ansoff Matrix, Vaccine, Pharmaceutical industry, Tuberculosis

The Global Respiratory Disease Vaccine Market is estimated to be USD 22.16 Bn in 2022 and is expected to reach USD 29.71 Bn by 2027, growing at a CAGR of 6.04%.

Key Points: 
  • The Global Respiratory Disease Vaccine Market is estimated to be USD 22.16 Bn in 2022 and is expected to reach USD 29.71 Bn by 2027, growing at a CAGR of 6.04%.
  • The Global Respiratory Disease Vaccine Market is segmented based on Infection, Type, Age Group, and Geography.
  • By Type, the market is classified into Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
  • The report offers a comprehensive evaluation of the Global Respiratory Disease Vaccine Market.

LEO Pharma Announces British Journal of Dermatology Publication of Adbry™ (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Wednesday, October 26, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Inactivated vaccine, Breast milk, Communication, Disease, Atopic dermatitis, Syringe, Development, Skin, Journal of the American Academy of Dermatology, Allergy, DPT vaccine, Vaccine, Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tell, Patient, NOS, AES, Food, Anaphylaxis, Publishing, British Journal of Dermatology, BAD, Wiley (publisher), Association, Leo Pharma, Wiley, Adult, Safety, LEO, Dermatitis, AD, Vitamin, British Association of Dermatologists, Disease management, Hypersensitivity, TCS, Itch, Tralokinumab, FDA, Pharmaceutical industry, Dietary supplement, Health insurance, Birth control, Dermatology, Dermatology

Our ongoing clinical program continues to reveal new learnings and insights on the safety profile of Adbry.

Key Points: 
  • Our ongoing clinical program continues to reveal new learnings and insights on the safety profile of Adbry.
  • Safety remains a top priority for people with moderate-to-severe atopic dermatitis and the clinicians who treat them, as well as for LEO Pharma.
  • Adbry is approved for adult patients whose disease is not adequately controlled with topical prescription therapies or when those are not advisable.
  • The British Journal of Dermatology is owned by British Association of Dermatologists (BAD), the central association of practising UK dermatologists.

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona

Retrieved on: 
Tuesday, October 11, 2022
U.S. Securities and Exchange Commission, Water, Sepsis, Inactivated vaccine, Congress, Streptococcus pneumoniae, Risk, Media, SEC, Government, Cincinnati Children's Hospital Medical Center, Hospital, Vaccine, VLP, Research, Security (finance), Malaria, Nose, AOM, Subclinical infection, S&P, Private Securities Litigation Reform Act, Infection, University, Center, OH, American Lung Association, BWV, Nov, St. Jude Children's Research Hospital, Sinusitis, Bacteria, GLOBE, Korea Disease Control and Prevention Agency, Vaccination, Norovirus, Jude the Apostle, FDA, COVID-19, Pharmaceutical industry, Streptococcus

Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis.

Key Points: 
  • Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis.
  • BWVs new development plan aims to assess the efficacy of BWV-201 in protecting individuals against non-invasive pneumococcal pneumonia.
  • BWV-201 is a live attenuated bacterial vaccine candidate developed for the prevention of AOM in children caused by Streptococcus pneumoniae.
  • While current pneumococcal vaccines have demonstrated excellent efficacy against invasive pneumococcal disease historically, pneumococcal pneumonia remains a significant unmet medical need, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.

Asia Pacific Travel Vaccines Market Report 2022: Surge in Incidences of Infectious Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Infectious Diseases, Pharmaceutical, Health, Rotavirus, Health, Hepatitis A, COVID-19, Risk, Vaccination, Growth, Hepatitis B, Immunization, Travel, Inactivated vaccine, Human papillomavirus infection, Pneumonia, Vaccine, HPV, Awareness, Infection, CAGR, Aquaculture

The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.
  • The Asia Pacific travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • The Asia Pacific travel vaccines market, based on application, is segmented into domestic travel and outbound travel.
  • Based on country, the Asia Pacific travel vaccines market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific.